Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) Return on Capital Employed (2020 - 2025)

Burning Rock Biotech has reported Return on Capital Employed over the past 6 years, most recently at 9.56% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 4272.0% year-over-year to 9.56%; the TTM value through Dec 2025 reached 9.56%, up 4272.0%, while the annual FY2025 figure was 9.21%, 4109.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 9.56% at Burning Rock Biotech, up from 21.03% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 9.56% in Q4 2025 and troughed at 83.32% in Q4 2022.
  • A 5-year average of 53.56% and a median of 55.49% in 2022 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -4317bps in 2022 and later soared 5448bps in 2025.
  • Year by year, Return on Capital Employed stood at 40.16% in 2021, then plummeted by -108bps to 83.32% in 2022, then increased by 1bps to 82.24% in 2023, then skyrocketed by 36bps to 52.27% in 2024, then surged by 82bps to 9.56% in 2025.
  • Business Quant data shows Return on Capital Employed for BNR at 9.56% in Q4 2025, 21.03% in Q3 2025, and 24.19% in Q2 2025.